Effect of Crestor (Rosuvastatin) on Lipid Levels in Patients With Metabolic Syndrome

Open-labelled, Single Arm, Phase IV Clinical Study to Evaluate the Impact of Rosuvastatin on Lipid Levels in Patients With Metabolic Syndrome (EFFORT)

The primary objective is to evaluate the efficacy of rosuvastatin therapy on plasma lipid profile (Low Density Lipoprotein (LDL), High-Density Lipoprotein (HDL), total cholesterol, triglyceride) in patients with metabolic syndrome.

Inclusion Criteria:

• metabolic syndrome (according to National Cholesterol Education Program (NCEP) Adenosine triphosphate (ATP) Ill criteria)
• LDL-Cholesterol > 130mg/dl
• HDL-Cholesterol < 40mg/dl in males and <50mg/dl in females
• Triglycerides < 400 mg/dl

Exclusion Criteria:

• With a concomitant coronary disease
• Currently under statin therapy or previously treated with statins within the last 6 months